Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Friday, up 0.93% from the previous trading day, before settling in for the closing price of $17.25. Over the past 52 weeks, BEAM has traded in a range of $13.52-$35.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 43280.87%. While this was happening, its average annual earnings per share was recorded -1.28%. With a float of $85.97 million, this company’s outstanding shares have now reached $100.56 million.
Let’s determine the extent of company efficiency that accounts for 483 employees. In terms of profitability, gross margin is 65.48%, operating margin of -654.25%, and the pretax margin is -593.06%.
Beam Therapeutics Inc (BEAM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 14.51%, while institutional ownership is 73.22%. The most recent insider transaction that took place on Apr 01 ’25, was worth 104,122. In this transaction Chief Legal Officer of this company sold 5,674 shares at a rate of $18.35, taking the stock ownership to the 117,294 shares. Before that another transaction happened on Apr 01 ’25, when Company’s CEO sold 30,663 for $18.35, making the entire transaction worth $562,684. This insider now owns 986,249 shares in total.
Beam Therapeutics Inc (BEAM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -1.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.72% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 8.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.61, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.71 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Looking closely at Beam Therapeutics Inc (NASDAQ: BEAM), its last 5-days average volume was 3.06 million, which is a jump from its year-to-date volume of 2.03 million. As of the previous 9 days, the stock’s Stochastic %D was 26.93%. Additionally, its Average True Range was 1.63.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 17.88%, which indicates a significant decrease from 35.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.59% in the past 14 days, which was higher than the 85.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.67, while its 200-day Moving Average is $24.74. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $18.32. Second resistance stands at $19.22. The third major resistance level sits at $19.70. If the price goes on to break the first support level at $16.94, it is likely to go to the next support level at $16.46. Now, if the price goes above the second support level, the third support stands at $15.56.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
The company with the Market Capitalisation of 1.75 billion has total of 100,557K Shares Outstanding. Its annual sales at the moment are 63,520 K in contrast with the sum of -376,740 K annual income. Company’s last quarter sales were recorded 30,070 K and last quarter income was -90,350 K.
